|
|
Volumn 93, Issue 5, 2011, Pages 586-593
|
|
Alemtuzumab for the prevention and treatment of graft-versus-host disease.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
CANCER ANTIBODY;
CD52 ANTIGEN;
CORTICOSTEROID;
GLYCOPROTEIN;
LEUKOCYTE ANTIGEN;
MONOCLONAL ANTIBODY;
TUMOR ANTIGEN;
ALLOTRANSPLANTATION;
B LYMPHOCYTE;
BLOOD DISEASE;
CLINICAL TRIAL (TOPIC);
DOSE CALCULATION;
DRUG ADMINISTRATION;
DRUG ADMINISTRATION ROUTE;
DRUG EFFECT;
GRAFT VERSUS HOST REACTION;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
IMMUNOLOGY;
IMMUNOSUPPRESSIVE TREATMENT;
LYMPHOCYTE TRANSFUSION;
METABOLISM;
MORTALITY;
NATURAL KILLER CELL;
OPPORTUNISTIC INFECTION;
PATHOLOGY;
PATHOPHYSIOLOGY;
RECURRENT DISEASE;
REVIEW;
SURVIVAL;
T LYMPHOCYTE;
ADRENAL CORTEX HORMONES;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTIGENS, CD;
ANTIGENS, NEOPLASM;
B-LYMPHOCYTES;
CLINICAL TRIALS AS TOPIC;
DRUG ADMINISTRATION ROUTES;
DRUG ADMINISTRATION SCHEDULE;
DRUG DOSAGE CALCULATIONS;
GLYCOPROTEINS;
GRAFT VS HOST DISEASE;
HEMATOLOGIC NEOPLASMS;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
KILLER CELLS, NATURAL;
LYMPHOCYTE TRANSFUSION;
OPPORTUNISTIC INFECTIONS;
RECURRENCE;
SURVIVAL ANALYSIS;
T-LYMPHOCYTES;
TRANSPLANTATION CONDITIONING;
TRANSPLANTATION, HOMOLOGOUS;
|
|
EID: 80052907491
PISSN: None
EISSN: 18653774
Source Type: Journal
DOI: 10.1007/s12185-011-0802-2 Document Type: Review |
|
Times cited : (51)
|
|
References (0)
|
